GC
GNCA

Guggenheim Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Guggenheim Capital’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,588
Closed -$13K – 2747
2018
Q1 		$13K Buy
+1,588
New +$13.2K ﹤0.01% 2758

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Guggenheim Capital's GNCA Position: Q2 2018 in Review

Guggenheim Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 1,588 shares — an estimated $13K sold.

Guggenheim Capital first reported a position in GNCA in Q1 2018 and held it in 1 quarter. The position peaked at $13K in Q1 2018. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

  • Guggenheim Capital reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 1,588 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $13K.
  • Guggenheim Capital first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 1 quarter.
  • Guggenheim Capital's Genocea Biosciences, Inc. position peaked at $13K in Q1 2018.
  • 54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.